Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 569,094
  • Shares Outstanding, K 14,444
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,890 K
  • 60-Month Beta 0.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.32

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.33
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -40.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.02 +78.93%
on 06/14/19
46.90 -15.99%
on 06/25/19
+6.96 (+21.46%)
since 05/24/19
3-Month
22.02 +78.93%
on 06/14/19
46.90 -15.99%
on 06/25/19
+12.09 (+44.27%)
since 03/26/19
52-Week
13.75 +186.55%
on 06/27/18
46.90 -15.99%
on 06/25/19
+24.88 (+171.35%)
since 06/26/18

Most Recent Stories

More News
Krystal Biotech Announces Pricing of $100.0 Million Public Offering of Common Stock

Krystal Biotech, Inc. (Nasdaq: KRYS) (the "Company"), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced...

KRYS : 39.40 (-2.26%)
Krystal Biotech Announces Proposed $100 Million Public Offering of Common Stock

Krystal Biotech, Inc. (Nasdaq: KRYS) (the "Company"), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced...

KRYS : 39.40 (-2.26%)
Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial ("GEM-2 study") of KB103 and Receives Regenerative Medicine Advanced Therapy ("RMAT") Designation from FDA for KB103

-- Safety data from all patients show that KB103 was well tolerated with no adverse events reported

KRYS : 39.40 (-2.26%)
Krystal Biotech to Present at the RBC Capital Markets 2019 Healthcare Conference

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that Krish S. Krishnan, chairman and chief executive officer,...

KRYS : 39.40 (-2.26%)
Krystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update

EMA grants PRIME eligibility for KB103 (bercolagene telserpavec) to treat dystrophic epidermolysis bullosa

KRYS : 39.40 (-2.26%)
Krystal Biotech Announces Five Presentations of Clinical and Preclinical Data at the Society for Investigative Dermatology Annual Meeting

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations of clinical data for KB103 to treat dystrophic epidermolysis...

KRYS : 39.40 (-2.26%)
New Research: Key Drivers of Growth for SeaChange International, State Auto Financial, GWG, Krystal Biotech, Superior Drilling Products, and OHA Investment -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SeaChange International, Inc....

GWGH : 6.78 (-12.97%)
SEAC : 1.30 (-3.70%)
KRYS : 39.40 (-2.26%)
OHAI : 1.14 (+5.56%)
STFC : 33.69 (-1.64%)
SDPI : 1.04 (unch)
EMA Grants PRIME Eligibility for KB103 to Treat Dystrophic Epidermolysis Bullosa

First EMA PRIME eligibility for Krystal Biotech

KRYS : 39.40 (-2.26%)
Krystal Biotech Reports 2018 Financial Results and Business Progress

Topline-data from Phase 1/2 clinical trial of KB103 (bercolagene telserpavec) for treatment dystrophic epidermolysis bullosa (DEB) to be announced in 1H 2019

KRYS : 39.40 (-2.26%)
Krystal (KRYS) in Focus: Stock Moves 5.1% Higher

Krystal (KRYS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

KRYS : 39.40 (-2.26%)
CELC : 20.07 (-0.89%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More Share

Trade KRYS with:

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

2nd Resistance Point 43.68
1st Resistance Point 41.54
Last Price 39.40
1st Support Level 37.72
2nd Support Level 36.04

See More

52-Week High 46.90
Last Price 39.40
Fibonacci 61.8% 34.24
Fibonacci 50% 30.33
Fibonacci 38.2% 26.41
52-Week Low 13.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar